This article has been updated to correct the name of Clinical Genomics' ctDNA methylation test. It is Colvera, not ColoVantage.

NEW YORK (GenomeWeb) – Clinical Genomics has published a study demonstrating that its epigenetics-based ctDNA test picks up twice the number of colorectal cancer recurrences as currently used blood tests for carcinoembryonic antigen (CEA).

The study was published online this month in Cancer Medicine and will also appear in the journal's October print issue.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep.